Canada's CCAB likes India for manufacturing its antibody products; Alveda buys IGI Laboratories;

> After partnering with India's Zydus Cadila for its first antibody-based cancer treatments, Canada's Centre for Commercialisation of Antibodies and Biologics (CCAB) says it is impressed by India's manufacturing capabilities and will look for partnerships there for some of its other 1,000 antibodies. Report

> Canada's Alveda Pharmaceuticals, which uses European CMOS to produce its generic injectable drugs, will be acquired by New Jersey based IGI Laboratories, for $47 million. Report

> Mankind Pharma says it has invested Rs 150 crore ($23 million) in its plant at Paonta Sahib and expects to add 35 nutraceutical, food supplement and beverage products by the end of next year. Report

And Finally... Former NBA star Lamar Odom was found unconscious in a Nevada brothel, whose owner said Odom had taken large amounts of an herbal Viagra that the FDA had warned consumers about. Story

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.